Integrated Filing — IndAS



General information about company
Scrip Code 540797
NSE Symbol SHALBY
MSEI Symbol NOTLISTED
ISIN INE597J01018
Name of company SHALBY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 29-May-2025   17:20:00
End date and time of board meeting 29-May-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-03
Indicate Company website link for updated RPT policy of the Company httpswww.shalby.orgwpcontentuploads201801RelatedPartyTransactionPolicyv61pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There was no default on Loans and there are no debt securities during the quarter ended March 31, 2025



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2070570000 8726830000
Other income 71390000 264430000
Total income 2141960000 8991260000
2 Expenses
(a) Cost of materials consumed 530470000 2123860000
(b) Purchases of stock-in-trade 28830000 118210000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 1270000 -450000
(d) Employee benefit expense 260510000 1090100000
(e) Finance costs 26590000 111140000
(f) Depreciation, depletion and amortisation expense 96260000 388870000
(f) Other Expenses
1 Fees To Doctors & Consultants 589260000 2289250000
2 Other Expenses 169400000 717820000
3 Other Operative Expenses 182570000 795060000
Total other expenses 941230000 3802130000
Total expenses 1885160000 7633860000
3 Total profit before exceptional items and tax 256800000 1357400000
4 Exceptional items 0 0
5 Total profit before tax 256800000 1357400000
6 Tax expense
7 Current tax 99290000 552380000
8 Deferred tax 7930000 -32890000
9 Total tax expenses 107220000 519490000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 149580000 837910000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 149580000 837910000
17 Other comprehensive income net of taxes 310000 2030000
18 Total Comprehensive Income for the period 149890000 839940000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1074870000 1074870000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 10265070000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.39 7.8
Diluted earnings (loss) per share from continuing operations 1.39 7.8
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.39 7.8
Diluted earnings (loss) per share from continuing and discontinued operations 1.39 7.8
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1 The above Standalone financial results for the quarter and year ended March 31 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on May 29 2025 The Statutory Auditors of the Company have expressed unmodified opinion on the aforesaid results n n2.These financial results have been prepared in accordance with Indian Accounting Standards Ind AS as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies Indian Accounting Standards Rules 2015 and relevant amendment thereafter n n3.The figures for quarter ended 31st March 2025 and for corresponding quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year to date figures up to the third quarter of the respective financial year. n n4.Shalby Limited Employees Welfare Trust has acquired 700000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme 2021 During the quarter ended March 31 2025 the Company has granted 205265 Stock Options to eligible employees Till March 31 2025 Company has granted all 700000 Stock Options to eligible employees out of which total 313265 Stock Options were lapsed and 177235 Options were vested and exercised by eligible employees. n nIn accordance with the resolution passed by the Nomination and Remuneration Committee the Company has granted 9000 stock options from the pool of 313265 lapsed options and as of March 31 2025 a total of 218500 stock options remain active. n n5.During the previous year the Company has acquired 87.26 percent stake in shareholding of PK Healthcare Private Limited through preferential allotment of equity shares and secondary acquisition from promoters during January 2024. PK Healthcare Pvt. Ltd. is now a subsidiary of the Company Effective form 25th January 2024. n n6.During the previous year the Company has acquired 100 percent stake in shareholding of Healers Hospital Private Limited through secondary acquisition from existing shareholders during March 2024. Healers Hospital Pvt. Ltd. is now wholly owned subsidiary of the Company effective from 15th March 2024. n n7. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular dated 26th November 2018. n n8.The Code on Social Security 2020 relating to employee benefits during employment and post employment benefits has received Presidential assent and has been published in the Gazette of India. However the effective date of the Code and final rules for quantifying the financial impact are yet to be notified. The Group will assess the impact of the Code when relevant provisions are notified and will record related impact if any in the period the Code becomes effective. n n9.The Company s operating segment is Medical and Healthcare Related Services. Since the Company has a single operating segment disclosure pertaining to segment as per the regulation 33 1 e read with clause L of Part A of Schedule IV of the SEBI Regulations is not applicable. n n10.Previous period figures have been re grouped re cast and re arranged wherever considered necessary to make it comparable. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 5549700000
Capital work-in-progress 80420000
Investment property 0
Goodwill 81970000
Other intangible assets 157760000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 3558230000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 517510000
Total non-current financial assets 4075740000
Deferred tax assets (net) 0
Other non-current assets 0
Total non-current assets 9945590000
2 Current assets
Inventories 201270000
Current financial asset
Current investments 2431490000
Trade receivables, current 1317050000
Cash and cash equivalents 215960000
Bank balance other than cash and cash equivalents 580000
Loans, current 430000000
Other current financial assets 156090000
Total current financial assets 4551170000
Current tax assets (net)
Other current assets
Total current assets 4752440000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 14698030000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1074870000
Other equity 10265070000
Total equity attributable to owners of parent 11339940000
Non controlling interest
Total equity 11339940000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 853960000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 57050000
Total non-current financial liabilities 911010000
Provisions, non-current 45150000
Deferred tax liabilities (net) 1104020000
Deferred government grants, Non-current 0
Other non-current liabilities 75050000
Total non-current liabilities 2135230000
Current liabilities
Current financial liabilities
Borrowings, current 177930000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 38610000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 755840000
Total Trade payable 794450000
Other current financial liabilities 110680000
Total current financial liabilities 1083060000
Other current liabilities 108410000
Provisions, current 31390000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 1222860000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 3358090000
Total equity and liabilites 14698030000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 470000 3130000
Total Amount of items that will not be reclassified to profit and loss 470000 3130000
2 Income tax relating to items that will not be reclassified to profit or loss 160000 1100000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 310000 2030000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1357400000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 111140000
Adjustments for decrease (increase) in inventories -26510000
Adjustments for decrease (increase) in trade receivables, current -143300000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -6900000
Adjustments for decrease (increase) in other non-current assets 14090000
Adjustments for other financial assets, non-current -2330000
Adjustments for other financial assets, current -3610000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 61580000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -1560000
Adjustments for increase (decrease) in other non-current liabilities -10610000
Adjustments for depreciation and amortisation expense 388860000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 15440000
Adjustments for other financial liabilities, current -4340000
Adjustments for other financial liabilities, non-current -600000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 86290000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -80360000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 25270000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships -5040000
Total adjustments for reconcile profit (loss) 244930000
Net cash flows from (used in) operations 1602330000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 114090000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 1488240000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 750000000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1500000
Purchase of property, plant and equipment 230880000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets -345430000
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties -415000000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 77400000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -34730000
Net cash flows from (used in) investing activities -1006280000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 1380000
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 108350000
Payments of lease liabilities 17740000
Dividends paid 129610000
Interest paid 103650000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -357970000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 123990000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 123990000
Cash and cash equivalents cash flow statement at beginning of period 91980000
Cash and cash equivalents cash flow statement at end of period 215970000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 T R CHADHA & CO LLP Yes 30-Sep-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Shalby Limited Dr Darshini V Shah Relative of Key Management Personnel Purchase of goods or services NA 10900000 0 2190000
2 Shalby Limited Dr Nishita Shukla Key Management Personnel KMP Remuneration NA 5390000 0 0
3 Shalby Limited Dr Vikram I. Shah Promoter and Key Management Personnel KMP Purchase of goods or services NA 7290000 1950000 810000
4 Shalby Limited Mr Amit Pathak Key Management Personnel KMP Remuneration NA 3120000 0 0
5 Shalby Limited Mr Shanay Shah Promoter and Key Management Personnel KMP Remuneration NA 4390000 0 0
6 Shalby Limited Tushar Shah Key Management Personnel KMP Remuneration NA 1750000 0 0
7 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Any other transaction Profit Share NA 2170000 19570000 0
8 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Interest received NA 380000 0 0
9 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Investment NA 0 480000 480000
10 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Purchase of goods or services NA 345630000 117580000 142200000
11 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Sale of goods or services NA 30000 40000 40000
12 Shalby Limited Mars Medical Devices Limited Subsidiary Entity Any other transaction Loan Given NA 408870000 0 0 Loan 0 On Demand Loan 0.086 On Demand Unsecured General Corporate Purpose
13 Shalby Limited Mars Medical Devices Limited Subsidiary Entity Any other transaction Loan Recevied NA 328870000 0 80000000
14 Shalby Limited Mars Medical Devices Limited Subsidiary Entity Investment NA 750000000 500000000 1250000000
15 Shalby Limited Mars Medical Devices Limited Subsidiary Entity Interest received NA 6640000 0 3900000
16 Shalby Limited Mars Medical Devices Limited Subsidiary Entity Investment NA 0 1500000000 1500000000
17 Shalby Limited Shalby Advanced Technologies Inc Step down Subsidiary company Any other transaction Advance for Exp NA 0 0 0
18 Shalby Limited Shalby Advanced Technologies Inc Step down Subsidiary company Any other transaction Corporate Guarantee in USD $ NA 0 0 0
19 Shalby Limited Shalby Advanced Technologies Inc Step down Subsidiary company Any other transaction Gurantee Givenn NA 11010000 3422150000 0
20 Shalby Limited Shalby Advanced Technologies Inc Step down Subsidiary company Any other transaction Reimbursement of Exp on behalf of Subcidiaryn NA 10320000 0 0
21 Shalby Limited Shalby Global Technology Pte Ltd Step down Subsidiary company Any other transaction ESOP Compensation expenses NA 0 0 0
22 Shalby Limited Shalby Hospitals Mumbai Pvt Ltd Subsidiary Company Investment NA 0 100000 100000
23 Shalby Limited Shalby International Limited Subsidiary Company Advance NA 0 0 0
24 Shalby Limited Shalby International Limited Subsidiary Company Investment NA 0 500000 500000
25 Shalby Limited Shalby Kenya Limited Subsidiary Company Advance NA 7640000 15070000 0
26 Shalby Limited Shalby Kenya Limited Subsidiary Company Sale of goods or services NA 4030000 0 0
27 Shalby Limited Shalby Kenya Limited Subsidiary Company Investment NA 0 60000 60000
28 Shalby Limited Shalby Orthopedic Hospital and Research Centre Enterprise over which KMP or Relatives of KMP exercise significant influence through controlling interest Other related Party Any other transaction Rent Income NA 300000 320000 50000
29 Shalby Limited Slaney Healthcare Pvt Ltd Subsidiary Company Investment NA 0 11210000 11210000
30 Shalby Limited Slaney Healthcare Pvt Ltd Subsidiary Company Any other transaction Royalty NA 7840000 8510000 16680000
31 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Company Advance NA 0 0 0
32 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Company Investment NA 0 229730000 0
33 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Company Any other transaction Rent Income NA 1150000 0 30000
34 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Company Any other transaction Sale NA 0 0 0
35 Shalby Limited Yogeshwar Healthcare Limited Subsidiary Company Investment NA 0 6960000 0
36 Shalby Limited Yogeshwar Healthcare Limited Subsidiary Company Any other transaction Trade Advance Given NA 0 0 0
37 Shalby Limited Yogeshwar Healthcare Limited Subsidiary Company Any other transaction Trade Advance Received NA 0 0 0
38 Shalby Limited Yogeshwar Healthcare Limited Subsidiary Company Any other transaction Reimbursement of Exp on behalf of Subsidiaryn NA 0 0 0
39 Shalby Limited Zodiac Mediquip Limited Promotor Company Any other transaction Commission Incomen NA 130000 0 140000
40 Shalby Limited Zodiac Mediquip Limited Promotor Company Any other transaction Guest House Expensesn NA 840000 230000 0
41 Shalby Limited Zodiac Mediquip Limited Promotor Company Any other transaction ESOP Compensation expenses NA 0 0 0
42 Shalby Limited Mars Medical Devices Limited Subsidiary Company Any other transaction ESOP Compensation expenses NA 820000 270000 100000
43 Shalby Limited Dr Vikram I Shah Promoter and Key Management Personnel KMP Purchase of goods or services NA 4850000 0 780000
44 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Investment NA 0 1019200000 0
45 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Any other transaction Loan Given NA 80120000 150000000 0 Loan 0 On Demand Loan 0.086 On Demand Unsecured General Corporate Purpose
46 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Any other transaction Loan Recevied NA 119880000 0 0
47 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Interest received NA 10930000 3280000 3500000
48 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Sale of goods or services NA 320000 970000 0
49 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Any other transaction Corporate Guarantee Commission NA 4900000 0 0
50 Shalby Limited P K Healthcare Pvt Ltd wef 24th January 2024 Subsidiary Company Any other transaction ESOP Compensation expenses NA 3810000 970000 0
51 Shalby Limited Healers Healthcare Pvt Ltd wef 15th March 2024 Subsidiary Company Investment NA 0 1040000000 0
Total value of transaction during the reporting period 2144320000